Biora Therapeutics Granted Extension To Regain Compliance With Nasdaq Listing Requirements
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics has been granted an extension by Nasdaq to regain compliance with its listing requirements. This extension provides the company with additional time to meet the necessary criteria to remain listed on the exchange.
August 28, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biora Therapeutics has been granted an extension by Nasdaq to regain compliance with listing requirements, providing more time to meet necessary criteria.
The extension from Nasdaq allows Biora Therapeutics more time to meet compliance requirements, which is crucial for maintaining its listing. This news is neutral in the short term as it does not immediately resolve the compliance issue but provides a pathway to potentially do so.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100